X4 Pharmaceuticals: Investor Webinar on Mavorixafor: Phase 1b Clinical Data in Chronic Neutropenia
About The Event
Join us for X4 Pharmaceuticals’ webinar presenting Phase 1b clinical trial data of mavorixafor in the treatment of Chronic Neutropenia Disorders, including severe congenital, idiopathic, and cyclic neutropenia.
The event will include perspectives from patients and clinical experts on the unmet medical needs and the opportunity for an innovative new treatment option.
Mavorixafor is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 that is being developed as a once-daily, oral therapy. X4 has advanced mavorixafor into Phase 3 clinical development in WHIM syndrome, a rare primary immunodeficiency. This webinar aims to highlight the potential of mavorixafor to treat a broader neutropenia population beyond those patients with WHIM syndrome.
A live Q&A will follow the formal presentations.